Why depot antipsychotic drug use in the treatment of psychotic disorders is still important? An investigation regarding clinical outcome;Psikotik bozukluklarin tedavisinde depo antipsikotik i̇laç (flufenazin dekanoat) kullanimi neden hâlâ önemlidir?: Klinik sonuç açisindan bir i̇nceleme

Klinik Psikofarmakoloji Bulteni

Volumn 16, Issue 2, 2006, Pages 98-103

  Yildiz, Mustafa ^a   Yüksel, A Gülşah ^b  

^a KOCAELI UNIVERSITY   (Turkey)

^b Kizilay Tip Merkezi   (Turkey)

Author keywords

Clinical outcome; Delusional disorder; Depot antipsychotic drugs; Pharmacotherapy; Schizophrenia; Treatment noncompliance

Indexed keywords

CHLORPROMAZINE; FLUPHENAZINE DECANOATE; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DELUSIONAL DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMAN; OUTPATIENT DEPARTMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 33745903406     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull 1997; 23:637-651
2. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51:216-222
3. Norquist GS, Regier DA. The epidemiology of psychiatric disorders and the de facto mental health care system. Annu Rev Med 1996; 47:473-479
4. Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q 1997; 68:377-392
5. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21:419-429
6. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161:692-699
7. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994; 10:464-479
8. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: Our patients can do better. J Clin Psychiatry 2003; 64:1308-1315
9. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998; 172:413-419
10. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 159:1653-1664
11. Kane JM, Leucht S, Carpenter D, Docherty JP. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003; 64(Suppl 12):5-19
12. Bechdolf A, Knost B, Kuntermann C, Schiller S, Klosterkotter J, Hambrecht M, Pukrop R. A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. Acta Psychiatr Scand 2004; 110:21-28
13. Patel MX, David AS. Why aren't depot antipsychotics prescribed more often and what can be done about it. Advances in Psychiatric Treatment 2005; 11:203-213
14. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindstrom E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998; 8:55-66
15. Chue P. Compliance and convenience: Do physicians and patients see depot medication differently? Acta Neuropsychiatr 2004; 16:314-318
16. Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47:741-773
17. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159:103-108
18. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new generation antipsychotics. A systematic review and explorative metaanalysis of randomized controlled trials. Am J Psychiatry 2003; 160:1209-1222
19. Bowen J, Barnes TRE. The clinical characteristics of schizophrenic patients consenting and not consenting to a placebo-controlled trial. Human Psychopharmacology 1994; 9:423-433
20. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychophar 2004; 14:87-92
21. Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors. Schizophr Bull 2004; 30:255-264
22. Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004; 19: 241-249
23. Adams CE, Fenton MKP, Quraishei S, David AS. Systemic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179:290-299
24. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E. Intramuscular preparations of antipsychotics: Uses and relevance in clinical practice. Drugs 2003; 63: 493-512
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association, 1994
26. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1997; 13:261-276.
27. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Guy W (Edi.), DHEW Publication No. (ADM) 76. Rockville, MD. National Institute of Mental Health, 1976:218-221
28. Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001; 62:545-551
29. Fitzgerald P. Long-acting antipsychotic medication, restraint and treatment in the management of acute psychosis. Aust N Z J Psychiatry 1999; 33:660-666
30. Yildiz M. Psikotik bozukluklarin tedavi maliyeti. Turk Psikiyatri Derg 2005; 16:146-147
31. Nayak RK, Doose DR, Nair NPV. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol 1987; 27:144-150
32. Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, Mintz J, Conley R. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159:554-560